CDXS
Codexis Inc.
$2.57
+$0.09(+3.63%)
58
Overall
60
Value
70
Tech
44
Quality
Market Cap
$159.87M
Volume
1.75M
52W Range
$0.96 - $3.87
Target Price
$6.58
Company Overview
| Mkt Cap | $159.87M | Price | $2.57 |
| Volume | 1.75M | Change | +3.63% |
| P/E Ratio | -3.6 | Open | $2.56 |
| Revenue | $70.4M | Prev Close | $2.48 |
| Net Income | $-44.0M | 52W Range | $0.96 - $3.87 |
| Div Yield | N/A | Target | $6.58 |
| Overall | 58 | Value | 60 |
| Quality | 44 | Technical | 70 |
No chart data available
About Codexis Inc.
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Gilead Sciences (GILD) and Codexis (CDXS)
Howard Kim•3 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CDXS | $2.57 | +3.6% | 1.75M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |